Figure 1.
Antibody repertoire profiling on CFG and NCFGv2 reveals broad carbohydrate-recognition defects in symptomatic PADs. (A) Glycan-specific binding of serum IgG screened at 180 μg/mL on CFG glycan array version 5.1 (610 glycans) depicted as RFU. Screened sera were from cohorts with symptomatic HGG (n = 76), SPAD (n = 5), CVID (n = 25), CVID PPVlow (n = 6), or IgGSD (n = 8) or from HDs (n = 43). Significant values are reported (Kruskal-Wallis test). (B) Glycan-binding reactivity matrices for individual sera (HD, n = 12; SPAD, n = 5; IgGSD, n = 8; HGG, n = 11; CVID, n = 12) screened on the NCFGv2 and computed using the dendrogram clustering algorithm, as outlined in Materials and methods. Columns represent the antibody-reactivity profiles (reactivity of each specific glycan for the different sera samples), and the rows reflect the immune profiles for each patient subgroup based on the mean RFU values.